EBOVAC2 and the 7 other IMI-funded Ebola+ attended the Cross-topic EbolA+ meeting organised by IMI on 2 February 2016.
The EBOVAC1 & EBOVAC2 joint annual meetings were held in Paris on 20-22 January 2016.
The first French subjects were randomized in France on 9 December 2015 at Cochin Hospital and on the 10 December at Henri Mondor Hospital in France.
To find out more about Inserm's EBOVAC2 campaign to recruit volunteers for trials to test the vaccine against the Ebola virus (in French):
http://www.recherche-vaccinebola.fr/
Watch the video on Inserm's EBOVAC2 campaign (in French)
Page 5 of 7
NEWS
-
The Utility of a Two-Dose Ebola Vaccine Regimen Confirmed
In response to the 2014-2016 Ebola epidemic, the clinical development of a two-dose regimen of...
-
8th EBOVAC2 Newsletter
The 8th EBOVAC2 newsletter is available here. This newsletter announces the European Commission...
-
European Commission Approval for Janssen’s Ebola vaccine regimen
Johnson & Johnson announced on 1st July 2020 that the European Commission (EC) has granted...
-
Positive CHMP Opinion for Janssen's Ebola Vaccine Regimen
Johnson & Johnson Receives Positive CHMP Opinion for Janssen’s Investigational Preventive Ebola...
-
Ebovac2 at ECCMID 2019
An Ebovac2 poster was selected among 13 out of approx. 2 500 posters on the top rated of the...
-
Ebola: background
What is Ebola?
-
Phase 2 trials
Find out more about EBOVAC2 trials
-
Work programme
EBOVAC2 is organised into 6 workpackages (WP)
-
Ebola+ programme
Contributes to efforts to tackle a wide range of challenges in Ebola research
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 115861.
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA